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Modulation of Adipose Tissue Expression of Murine
Matrix Metalloproteinases and Their Tissue Inhibitors
With Obesity
Erik Maquoi,1 Carine Munaut,2 Alain Colige,3 De´sire´ Collen,1 and H. Roger Lijnen1
The potential role of the matrix metalloproteinase
(MMP) system in the pathophysiology of the adipose
tissue was investigated in a mouse model of nutrition-
ally induced obesity. mRNA levels of 16 MMPs and 4
tissue inhibitors of MMPs (TIMPs) were measured by
semiquantitative RT-PCR in adipose tissue isolated
from mice maintained for 15 weeks on a standard or
high-fat diet. In mice on standard diet, with the excep-
tion of MMP-8, all MMP and TIMP transcripts were
detected in both gonadal and subcutaneous depots. In
obese mice, the expression of MMP-3, -11, -12, -13, and
-14 and TIMP-1 mRNAs was upregulated, whereas that
of MMP-7, -9, -16, and -24 and TIMP-4 was downregu-
lated. Most MMP and TIMP mRNAs were expressed at
higher levels in stromal-vascular cells than in mature
adipocytes. Analysis of adipose tissue by in situ fluores-
cent zymography revealed MMP-dependent proteolytic
activities, demonstrating the presence of active MMPs
in the intact tissue. In vitro conversion of adipogenic
3T3-F442A cells into mature adipocytes was associated
with substantial modulations of MMP and TIMP expres-
sion. Moreover, this in vitro adipogenesis was reduced
in the presence of a synthetic MMP inhibitor. Thus, the
adipose tissue expresses a large array of MMPs and
TIMPs, which modulate adipocyte differentiation.
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A dipose tissue is composed of lipid-filled cells(adipocytes) surrounded by collagen fibers,blood vessels, nerves, fibroblasts, and immunecells. Until recently, white adipose tissue was
considered an inert fat-storing tissue. However, recent
findings demonstrated that they play a dynamic role in the
highly regulated uptake, storage, and release of lipids.
Moreover, adipose tissue secretes several molecules, in-
cluding sex steroids, glucocorticoids, hormone precur-
sors, and cytokines, suggesting that it should be
considered an endocrine organ (1).
The chronic imbalance between energy intake and ex-
penditure results in obesity, a pathological condition of
the adipose tissue that is characterized by an excess of fat
mass resulting from an increase in the number and size of
the adipocytes (2,3). In most Western societies, obesity
has reached epidemic proportions and constitutes an
increased risk for the development of several pathologies,
including type 2 diabetes, insulin resistance, cardiovascu-
lar disease, and atherosclerosis (4,5).
Development of obesity is associated with an extensive
reorganization of the adipose tissue that involves adipo-
genesis, angiogenesis, and remodeling of the extracellular
matrix (ECM) (6). Two major proteolytic systems, the
serine proteinases and matrix metalloproteinases (MMPs),
have been implicated in several pathophysiological pro-
cesses involving extensive ECM remodeling (7). Plasmin-
ogen activator inhibitor-1 (PAI-1), the primary inhibitor of
tissue-type and urokinase-type plasminogen activators, is
highly expressed in adipose tissue of obese mice and
humans (8,9), suggesting a role for this proteinase family
in the adipose tissue. In contrast, little is known of the
potential involvement of MMPs in the physiology and
pathology of fat tissue.
The MMPs belong to a family of 23 neutral endopep-
tidases that are collectively able to cleave all of the ECM
components as well as several non-ECM proteins, such as
adhesion molecules, cytokines, proteinase inhibitors, and
other MMPs (10–12). MMPs are highly regulated enzymes
with expression, secretion, and activity levels under tight
control (13). In most cases, MMPs are expressed at
very-low levels; however, expression is rapidly induced at
times of active tissue remodeling. MMPs are synthesized
as latent precursors that have to be proteolytically acti-
vated to generate fully mature enzymes. MMP activity is
further modulated through interactions with tissue inhib-
itors of MMPs (TIMPs) (14). Four TIMPs have been
characterized and most are able to inhibit the activities of
all known MMPs. Consequently, the net MMP activity in
tissues is locally determined by the balance between the
levels of activated MMPs and TIMPs.
It is generally accepted that alterations in gene expres-
sion may contribute to the pathogenesis of obesity. To
gain further insight into the involvement of the MMPs in
the pathophysiology of adipose tissue, we monitored the
expression of MMPs and TIMPs in an in vivo mouse model
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of nutritionally induced obesity as well as in an in vitro
model of adipogenesis.
RESEARCH DESIGN AND METHODS
Experimental protocol. Five-week-old male wild-type mice (mixed 75%
C57/Bl6:25% 129Svj genetic background) were maintained on a standard-fat
diet (SFD) (4% [wt/wt] fat, n  11) or given a high-fat diet (HFD) (21% [wt/wt]
fat coming from milk fat, and 49% [wt/wt] carbohydrate coming from sucrose
and corn starch, n 11) (Harlan TD 88137; Harlan, Zeist, the Netherlands) for
15 weeks. The SFD contained 13% kcal as fat, and the HFD contained 42% kcal
as fat. After fasting overnight, the mice were weighed and killed with an
overdose (60 mg/kg i.p.) of Nembutal (Abbott Laboratories, North Chicago,
IL). Intra-abdominal (gonadal) and inguinal subcutaneous fat pads were
removed and weighed. Fat pads were either prepared for histology or
immediately frozen in liquid nitrogen and stored at 80°C. Blood samples
were obtained from the retroorbital sinus, and glucose concentrations were
measured with Glucocard strips (Menarini Diagnostics). All animal experi-
ments were approved by the local ethical committee and performed in
accordance with the guiding principles of the American Physiological Society
and the International Society on Thrombosis and Hemostasis (15).
Histological analysis. The mean diameter of adipocytes was determined by
computer-assisted image analysis (Quantimed 600; Leica, Hamburg, Germany)
in 15-m frozen-cut adipose tissue sections stained with hematoxylin-eosin.
For each animal, three to four sections were analyzed (four fields per section)
and averaged.
In situ fluorescent zymography of cryosections of adipose tissue using
casein- or gelatin-containing gels was performed essentially as described (16).
The substrate gel (0.5% agarose) contained 1 mg/ml resorufin-labeled casein
(Boehringer Mannheim, Mannheim, Germany) or pig skin gelatin Oregon
Green-488 conjugate (Molecular Probes Europe BV, Leiden, the Netherlands).
Overlays were analyzed by fluorescent microscopy after 48 h incubation at
37°C; lysis of the substrate gel was expressed in percent of section area.
Adipose tissue dissociation. Pooled gonadal or subcutaneous fat pads
dissected from mice maintained on SFD (n  5) or HFD (n  4) were used to
separate mature adipocytes from stromal-vascular (S-V) cells by collagenase
treatment (17). Briefly, minced fat pads were digested in Krebs-Ringer
bicarbonate buffer (KRBB) (Sigma Chemicals, St. Louis, MO) (pH 7.3)
supplemented with 3% (wt/vol) albumin (KRBB-BSA) and 1.5 mg/ml collage-
nase (Sigma) at 37°C for 1 h. Undigested tissue fragments were removed by
filtration through a 250-m nylon screen. Adipocytes were separated by their
ability to float on low-speed centrifugation. The floating fat cells were
resuspended in KRBB-BSA, washed, and centrifuged as described above. The
first and second pellets containing S-V cells were pooled. Erythrocytes
contaminating the S-V fraction were eliminated using Red Blood Cell Lysis
Buffer (Roche Molecular Biochemicals, Mannheim, Germany) according to the
manufacturer’s instructions. The two cell populations were washed and
resuspended in PBS.
Culture and differentiation of 3T3-F442A cells. 3T3-F442A preadipocytes
(gift from Prof. R. Ne´grel, University of Nice, France) were routinely grown in
basal medium: Dulbecco’s modified Eagle’s medium (DMEM)/nutrient mix
F12 (1:1) (Life Technologies, Merelbeke, Belgium) containing 100 mmol/l
pantothenate, 1 mmol/l biotin, 2.5 mmol/l glutamine, and 15 mmol/l HEPES,
supplemented with 10% (vol/vol) FBS (fetal bovine serum) (Life Technolo-
gies). To induce differentiation, cells were seeded at 3.6  104 cells/cm2 and
grown to confluence in basal medium with 10% FBS. Confluent cultures (day
0) were washed in serum-free basal medium and treated for 5 days with an
induction medium: basal medium supplemented with BSA (100 mg/l), ITS (10
mg/l insulin, 5.5 mg/l transferrin, and 5 g/l selenium) (Sigma), 10 nmol/l
dexamethasone, 250 mol/l methylisobutylxanthine, and 1 nmol/l triiodothy-
ronine (T3). Cultures were then switched to a differentiation medium (basal
medium supplemented with ITS and T3) for 2 weeks (induction and differen-
tiation media were renewed every 2–3 days). The influence of MMP inhibition
on in vitro adipogenesis was investigated by supplementing both induction
and differentiation media with either vehicle (0.05% DMSO) (Sigma) or a
synthetic MMP inhibitor (0.1–10 mol/l CT1746) (CellTech, Slough, U.K.).
Cellular viability was assessed by cell counting, Trypan Blue dye exclusion
assay, and WST-1 assay (Roche Molecular Biochemicals) as previously
described (18). Briefly, cells that were or were not treated with CT1746 were
supplemented with WST-1 tetrazolium salt (10% vol/vol) and incubated for 2 h
at 37°C. WST-1 is cleaved to formazan by the mitochondrial dehydrogenases
of metabolically active cells. Accumulation of formazan was quantified by
spectophotometry.
Total RNAs and conditioned media were collected at various time points
during the differentiation process. Secretion of MMP-2, MMP-9, and TIMPs
into the culture medium was evaluated by gelatin zymography and reverse
zymography, respectively, as previously described (18,19).
Flow cytometric analysis. To assess the extent of preadipocyte differenti-
ation, cytosolic triglyceride content was quantified by determining Nile Red
uptake. Cells were harvested by treatment with trypsin (0.5 g/l), EDTA (0.2
g/l), and collagenase (2 g/l) in Hank’s balanced salt solution at 37°C, washed
in DMEM/nutrient mix F12 containing 10% FBS, and incubated for 10 min in
PBS containing Nile Red (10 g/ml) (Molecular Probes). Cells were subjected
to flow cytometric analysis (FACSCalibur; Becton Dickinson, Aalst, Belgium)
with 20,000 events collected per sample, as described (20). The 488-nm
excitation light was used to generate forward scatter and right-angle scatter
signals. Nile Red fluorescence was detected at 530 nm, and data were
expressed as a contour plot.
RNA isolation. DNA-free total RNAs were extracted from frozen adipose
tissue (gonadal and subcutaneous) as well as from isolated adipocytes, S-V
cells, and 3T3-F442A cells by the HighPure RNA tissue and HighPure RNA
isolation kits (Roche Molecular Biochemicals), respectively, according to the
manufacturer’s instructions. RNA concentrations were measured using the
RiboGreen RNA quantification kit (Molecular Probes). Total RNA samples
were diluted in water and stored at 80°C.
Oligonucleotide primers. The design of oligonucleotide primers specific for
the different targets was based on sequences available in the GenBank (Table
1). When the genomic sequence of the targets was available, primers (Euro-
gentec, Seraing, Belgium) annealing to distinct exons were selected in order to
discriminate between RT-PCR products resulting from the amplification of the
target mRNA or from contaminating genomic DNA. The specificity of the
different primer pairs was tested by subjecting RNA isolated from known
positive control tissue to RT-PCR (Table 1). RT-PCR products were cloned
into a pCRII-TOPO vector (Invitrogen, Groningen, the Netherlands) according
to the manufacturer’s instructions and cycle sequenced with M13R primer
(Invitrogen) on a GeneAmp 9700 thermal cycler using the BigDye Terminator
Cycle Sequencing Kit (Applied Biosystems, Nieuwerkerk a/d Ijssel, the Neth-
erlands). The PCR products were separated and analyzed on an ABI Prism 310
Genetic Analyzer (Applied Biosystems). The identity of the resulting se-
quences was verified with the NCBI BLASTN program.
Semiquantitative RT-PCR. The expression level of the different RNAs was
determined by semiquantitative RT-PCR. RT reactions were performed from
10 ng total RNA with thermostable RT (rTth) at 70°C for 15 min using the
GeneAmp Thermostable RNA PCR Kit (Applied Biosystems) and target-
specific antisense primers (Table 1). PCR amplifications were performed with
target-specific sense primers (Table 1). The reactions were run for the
corresponding number of cycles (Table 1) in a GeneAmp 9700 thermal cycler.
The number of cycles was optimized for each target so that the PCR products
did not reach plateau levels. RT-PCRs without sample were used as negative
controls. RT-PCR products were separated on 10% acrylamide gels and
stained with SYBR Green (Molecular Probes). The intensities of the bands
were quantified with the Gel Doc 2000 System using Quantity One software
(Bio-Rad, Eke, Belgium). To normalize the mRNA levels in the different
samples, the intensity of the band corresponding to each mRNA was divided
by the intensity of the band corresponding to the 28S rRNA, which was used
as an internal standard.
Statistical analysis. Data were reported as means  SE, and statistical
analysis was performed by Student’s t test. The correlations between mRNA
levels and adipose tissue weights were examined using the nonparametric
Spearman’s rank correlation coefficient test. Thresholds for significance were
set at P  0.05.
RESULTS
Nutritionally induced obesity in mice. Mice maintained
on HFD for 15 weeks had a significantly higher total body
weight than age-matched mice on SFD, and the weight of
their gonadal and subcutaneous fat pads was significantly
higher (Table 2). Expressed in percent of the total body
weight, gonadal fat represents 4.9  0.34% for mice on
HFD as compared with 1.1  0.10% for mice on SFD (P 
0.000001); corresponding values for subcutaneous fat are
4.6  0.29% vs. 1.0  0.14% (P  0.000001). The mean
diameter of the adipocytes was higher in both gonadal and
subcutaneous fat depots of mice on HFD (Table 2). The
HFD significantly increased blood glucose levels (Table 2).
Expression of MMPs and TIMPs in adipose tissue of
lean mice. Gonadal and subcutaneous depots isolated
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from 20-week-old mice maintained on SFD were analyzed
by semiquantitative RT-PCR. Except for MMP-8, all 16
MMPs and 4 TIMPs analyzed were detected in both
gonadal and subcutaneous adipose tissue (Fig. 1A). Al-
though the expression levels of most mRNAs did not
markedly differ between gonadal and subcutaneous fat,
the MMP-3 mRNA level was higher in subcutaneous than
in gonadal fat, whereas MMP-24 mRNA was lower in the
subcutaneous depot (Fig. 1A). However, the limited num-
ber of subcutaneous samples (n  2) obtained from lean
TABLE 1


























































































































216 Lung A 25/25/45
TIMP-4 (AI551619) ACTTGCTATGCAGTG
CCATG
TCGGTACCAGCTGCAGATG 144 Brain C 26/28/34
vWF (U27810) GGTCAGACGAAGTTG
GTGAAG
CCCCATTGAAGGCATACTCC 150 Lung C –/48/–
Pref-1 (L12721) AACCATGGCAGTGCA
TCTG
AGCATTCGTACTGGCCTTTC 132 Preadip C –/–/26










197 Adip A –/–/27




212 Lung A 19/17/17
*GenBank accession nos. of the targets are indicated in parentheses. †Cycle profiles A–C are as follows: after 120 s at 95°C, PCR mixtures
were subjected to a cycle profile, including denaturation for 15 s at 94°C, annealing for 20, 30, and 20 s at 68, 63, and 60°C, extension for 10,
30, and 10 s (A, B, and C, respectively) at 72°C and a 2-min extension at 72°C for the last cycle. ‡Number of cycles used to amplify sequences
in adipose tissue/isolated cell fractions/3T3 cells. Adip, adipocytes; preadip, preadipocytes; pref-1, preadipocyte factor-1; vWF, von
Willebrand factor.
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mice did not allow us to statistically compare the mRNA
levels between subcutaneous and gonadal fat.
Modulation of MMP and TIMP expression in fat pads
by nutritionally induced obesity. Next, we investigated
the expression of MMPs and TIMPs in adipose tissue from
mice maintained on HFD for 15 weeks. As for the lean
mice, all mRNAs investigated, with the exception of
MMP-8, were expressed in both gonadal and subcutaneous
depots of obese mice (Fig. 1B). In gonadal adipose tissue,
the HFD did not significantly affect the mRNA levels of
MMP-2, -10, -15, -17, -19, and -23 and TIMP-2 and -3. In
contrast, the expression of MMP-3, -11, -12, -13, and -14 and
TIMP-1 was increased, whereas MMP-7, -9, -16, and -24 and
TIMP-4 mRNA levels were downregulated (Fig. 1B). The
limited number of subcutaneous fat samples (n  2)
obtained from lean mice did not allow us to perform
statistical analysis on the modulations of the mRNA levels
induced by the HFD in that depot. Nevertheless, our data
suggest that, with the exception of MMP-12, -13, and -15
and TIMP-1, modulations similar to those observed in
gonadal fat also occurred in the subcutaneous depot (Fig.
1B).
Cellular localization of MMP and TIMP mRNAs in
adipose tissue. Gonadal and subcutaneous depots were
dissociated and mature adipocytes separated from the S-V
cells by centrifugation. Total RNA was isolated from the
resulting cell fractions and subjected to RT-PCR. Because
adipocytes have been shown to be intimately associated
with microvascular endothelial cells (21), we carefully
assessed the potential contamination of the adipocytes
with endothelial cells by determining the level of von
Willebrand factor mRNA (a marker of endothelial cells).
As expected, a specific band was observed in the S-V
fractions after a high number of PCR cycles, confirming
the presence of endothelial cells. Low expression levels
(ranging from 0.5 to 20% of those observed in the corre-
sponding S-V fractions) were also detected in some adipo-
cyte fractions, indicating the presence of a low number of
contaminating endothelial cells (Table 3).
In mice maintained on SFD, the expression of the
different MMP and TIMP mRNAs in isolated cell popula-
tions was heterogeneous and, for some of them, different
between gonadal and subcutaneous depots (Table 3).
Schematically, MMPs and TIMPs can be classified into
four groups based on their cellular distribution. A first
group, characterized by high expression levels in S-V cells
and no or only marginal expression in adipocytes, com-
prises MMP-2, -9, -11, -13, -14, -16, and -23 and TIMP-1 and
-2 (in both gonadal and subcutaneous fat), MMP-3, -7, and
-17 (in gonadal fat), and MMP-10 and -12 (in subcutaneous
fat). A second group, characterized by expression in both
S-V cells and adipocytes, but at higher levels in the former,
includes MMP-3 and -17 (in subcutaneous fat) and MMP-24
and TIMP-3 (in gonadal fat). A third group, characterized
by similar expression levels in S-V cells and adipocytes,
comprises MMP-10 (in gonadal fat), MMP-15, and TIMP-3
(both in subcutaneous fat). A fourth group, characterized
by higher expression levels in adipocytes, includes MMP-7
(in subcutaneous fat), MMP-12 and -15 (both in gonadal
fat), MMP-19, and TIMP-4 (in both gonadal and subcuta-
neous fat).
Collectively, these data reveal that in lean mice, mature
adipocytes expressed significant mRNA levels of a limited
number of MMPs (MMP-12, -15, -19, and -24) and TIMPs
(TIMP-3 and -4) and suggested a differential regulation of
FIG. 1. Expression of MMP and TIMP mRNAs in gonadal and subcuta-
neous adipose tissue. MMP and TIMP mRNA levels in gonadal () and
subcutaneous fat pads (f) collected from mice maintained for 15
weeks on SFD (A) or HFD (B) were determined by semiquantitative
RT-PCR. Relative expression levels were obtained after normalization
for the 28S rRNA levels. Data are means  SE obtained from the
analysis of gonadal fat from mice on SFD (n  6) or HFD (n  6) and
subcutaneous fat from mice on SFD (n 2) or HFD (n 6). Results are
expressed as normalized mRNA levels (A) or as percent of the expres-
sion level observed in mice on SFD (B). *P < 0.05, **P < 0.01 vs. values
obtained in gonadal fat from mice on SFD; °P < 0.05, °°P < 0.01 vs.
values obtained in gonadal fat from mice on HFD.
TABLE 2
Effect of 15 weeks of HFD on body weight and adipose tissue
weight and cellularity
SFD HFD
Body weight (g) 28  1.2 40  1.4*
Blood glucose (mg/dl)† 92  5.7 154  19‡
GON fat
Weight (g)† 0.31  0.04 2.0  0.18*
Adipocyte diameter (m)§ 42 83  3
SC fat
Weight (g)† 0.29  0.05 1.9  0.16*
Adipocyte diameter (m)§ 41 71  2
Data are means  SE. *P  0.000001 vs. SFD. †Totals of 10 and 11
determinations for SFD and HFD, respectively. ‡P  0.01 vs. SFD.
§Mean of two determinations for SFD, and means  SE of six
determinations for HFD. GON, gonadal; SC, subcutaneous.
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the expression of some mRNAs between gonadal and
subcutaneous depots (e.g. MMP-3, -7, and -12).
In mice on HFD, the expression profiles in isolated
adipocytes and S-V cells were similar to those observed in
the SFD groups, except for MMP-15 and -19 mRNAs (Table
3). Indeed, although these two mRNA species were very
abundant in adipocytes derived from mice on SFD, their
expression was lower in mice on HFD.
In situ detection of MMP activities in adipose tissue.
Because MMP activities in tissue are locally determined by
the balance between the levels of activated MMPs and
their inhibitors, we used in situ fluorescent zymography to
demonstrate the presence of MMP-dependent proteolytic
activities in intact adipose tissue from mice on HFD. On
the casein substrate, lysis corresponded to 19  3.4% (n 
5) of the section area with subcutaneous tissue and to
22  4.1% with gonadal tissue (P  NS); corresponding
values on the gelatin substrate were 8.0  2.7% and 6.9 
3.1% (n  5). The addition of EDTA (25 mmol/l) and
1,10-phenanthroline (5 mmol/l) resulted in 76  5.6% (n 
6) or 78  5.5% (n  7) inhibition of lysis on the casein or
gelatin substrate gel, respectively.
Correlations between MMP and TIMP mRNA levels
and degree of obesity. After 15 weeks of either SFD or
HFD, the individual total body weights of the mice ranged
from 20 to 47 g. A strong positive correlation was observed
between total body weight and the weight of either go-
nadal (
  0.95, P  0.000001) or subcutaneous fat (
 
0.94, P  0.000002), demonstrating that the weight of both
depots reflects the extent of obesity. Similar correlation
analysis performed for each mRNA species revealed that
the levels of MMP-3, -11, -12, -13, and -14 and TIMP-1 were
positively correlated with the weight of gonadal fat,
whereas negative correlations were observed for MMP-7,
-9, -16, and -24 and TIMP-4 (Table 4). With the exception of
MMP-9 and -11, such correlations were not detected in
subcutaneous depots.
TABLE 3
Expression of MMPs and TIMPs in isolated cells
mRNA species
SFD HFD
Adipocyte S-V Adipocyte S-V
GON SC GON SC GON SC GON SC
MMP-2      ()  
MMP-3        
MMP-7 ()       
MMP-9 ()       
MMP-10        
MMP-11        
MMP-12        
MMP-13        
MMP-14  ()      
MMP-15        
MMP-16  ()      ()
MMP-17        
MMP-19        ()
MMP-23     ()   ()
MMP-24  ()    ()  
TIMP-1        ()
TIMP-2 () ()   () ()  
TIMP-3     ()   
TIMP-4        
vWF* 21 9 100 100 0.5 3.5 100 100
Mature adipocytes and S-V cells were isolated from mice on SFD or HFD, and mRNA levels were analyzed by semiquantitative RT-PCR. After
normalization for 28S rRNA, the expression levels of the different mRNAs were scored on a scale from no () to high () expression.
*von Willebrand factor (vWF) was expressed in percent of the expression measured in the corresponding S-V fractions. GON, gonadal; SC,
subcutaneous.
TABLE 4
Correlations between MMP and TIMP mRNA levels and the
degree of obesity




MMP-2 0.482 0.112 0.683 0.042
MMP-3 0.881 0.0001 0.483 0.187
MMP-7 0.661 0.019 0.457 0.215
MMP-9 0.727 0.007 0.816 0.007
MMP-10 0.302 0.315 0.200 0.606
MMP-11 0.734 0.006 0.750 0.020
MMP-12 0.741 0.006 0.300 0.432
MMP-13 0.685 0.014 0.116 0.765
MMP-14 0.622 0.031 0.366 0.332
MMP-15 0.461 0.131 0.416 0.264
MMP-16 0.741 0.004 0.033 0.932
MMP-17 0.192 0.529 0.383 0.308
MMP-19 0.286 0.366 0.466 0.205
MMP-23 0.153 0.633 0.433 0.244
MMP-24 0.718 0.008 0.217 0.573
TIMP-1 0.780 0.002 0.483 0.187
TIMP-2 0.198 0.517 0.050 0.898
TIMP-3 0.020 0.948 0.633 0.067
TIMP-4 0.708 0.006 0.533 0.139
Spearman correlation coefficients for the relationships between
mRNA levels and the weight of the fat depot in gonadal (GON; n 
13) and subcutaneous (SC; n  9) adipose tissue. Statistically
significant differences (P  0.05) are underlined.
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Modulation of MMP and TIMP expression during in
vitro adipogenesis. We used 3T3-F442A preadipocytes as
an in vitro model of adipogenesis. Confluent cultures (day
0) were incubated with an induction medium containing
insulin, dexamethasone, methylisobutylxanthine, and T3
until day 5 and then maintained in a differentiation me-
dium (insulin and T3) for 2 weeks. This treatment induced
adipogenesis in a large percentage of the cells. The differ-
entiation was characterized by the conversion of preadi-
pocytes (Fig. 2A) into spherical lipid-filled adipocytes (Fig.
2E, insert). To monitor adipogenesis, flow cytometric
analyses were performed during the differentiation pro-
cess (Fig. 2F– J). Preadipocyte differentiation resulted in
the appearance of a population of cells characterized by
higher intensities of both Nile Red and side-scatter fluo-
rescences (compare Fig. 2A– E with 2F–J). Early signs of
differentiation were detected in untreated confluent cul-
tures (day 0), as judged from the presence of small
amounts of intracellular lipids (Fig. 2B and G) and by
increased levels of peroxisome proliferator–activated re-
ceptor (PPAR)-	 mRNA, a marker of early differentiation,
and glycerophosphate dehydrogenase (GPDH) mRNA, a
marker of the terminal phase of differentiation (Fig. 2L).
Treatment of confluent preadipocytes with the induction
medium resulted in a 80% decrease of preadipocyte fac-
tor-1, a marker of preadipocytes, mRNA level (Fig. 2M)
that was concomitant with a strong induction of PPAR-	
expression. As differentiation proceeded, GPDH expres-
sion increased simultaneously with the accumulation of
intracellular lipids (Fig. 2D, I, and N). After 19 days,
numerous lipid-filled adipocytes, characterized by lower
PPAR-	 and GPDH but high PAI-1 (a molecule expressed
at higher levels in fully differentiated adipocytes [21])
mRNA levels (Fig. 2E, J, and O), were observed.
Quantification of MMP and TIMP mRNA levels revealed
different expression profiles (Fig. 3A). mRNAs for MMP-2,
-3, -7, -10, -11, -12, and -13 increased throughout the
differentiation process and were maximal in mature adi-
pocytes (between days 12 and 19), as observed for PAI-1
(Fig. 2K– O). mRNAs for MMP-9 and -16 and TIMP-1 were
high in preconfluent cultures, decreased during early dif-
ferentiation, and increased as adipocytes matured. mRNAs
FIG. 2. 3T3-F442A preadipocytes as an in vitro model of adipogenesis. 3T3-F442A preadipocytes were cultured in serum-supplemented basal
medium until confluence (day 0). Cells were then treated with serum-free induction medium for 5 days and switched to serum-free differentiation
medium for 2 weeks. The conversion of preadipocytes into mature lipid-filled adipocytes was characterized by light microscopy (A–E), flow
cytometry (F–J), and semiquantitative RT-PCR (K–O) in preconfluent (A, F, K), confluent (B, G, L), 5 days (C, H, M), 12 days (D, I, N), and 19
days (E, J, O) postconfluent cultures. Flow cytometric data are contour plotted according to Nile Red fluorescence, which is indicative of dye
uptake into intracellular lipid droplets, and side-scatter (SSC-height) fluorescence, which reflects the cellular morphology. Mean values for Nile
Red (Nile) and side-scatter (SSC) fluorescence are indicated. Relative expression levels of preadipocyte factor-1, PPAR-, GPDH, and PAI-1 were
determined by semiquantitative RT-PCR. RT-PCR data are means of two independent experiments and are expressed as a percent of expression
level in preconfluent cultures (day 3).
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for MMP-14, -17, and -19 and TIMP-2 and -4 peaked early
and then later decreased during differentiation. mRNAs for
MMP-15 and -23 were expressed at very-low levels. MMP-8
and TIMP-3 mRNAs were not detected.
Measurement of MMP and TIMP secretion during the
differentiation process was performed by gelatin zymogra-
phy and reverse zymography (Fig. 3B and C). Latent
pro-MMP-2 (70- and 65-kDa bands) was the major proteo-
lytic enzyme detected by gelatin zymography. Its secretion
as well as its processing into active lower molecular
weight forms (61 and 58 kDa) were both increased during
differentiation. By day 19, an additional gelatinolytic activ-
ity of 94 kDa, corresponding to MMP-9, was observed.
Analysis of concentrated media by reverse zymography
revealed the presence of three TIMP activities (Fig. 3C).
Based on their apparent molecular sizes, these were most
likely TIMP-1 at a molecular weight of 30,000, TIMP-3
and/or -4 at a molecular weight of 23,000, and TIMP-2 at a
molecular weight of 20,000. Because of the absence of
detectable TIMP-3 mRNA in these cells, the inhibitory
activity of 23 kDa presumably corresponds to TIMP-4.
Inhibition of in vitro adipogenesis by a synthetic
MMP inhibitor. When confluent 3T3-F442A cultures were
differentiated in the presence of 10 mol/l CT1746 (a
synthetic hydroxamate-based MMP inhibitor), flow cyto-
metric analysis revealed an inhibition of lipid accretion
(Fig. 4). The inhibitor did not alter cellular viability, as
assessed by cell counting, Trypan Blue dye exclusion, and
WST-1 assay (data not shown), thus ruling out a potential
cytotoxic effect. Analysis of culture supernatants by gela-
tin zymography did not reveal any modulation of MMP
secretion by this inhibitor (data not shown). Addition of
CT1746 (10 mol/l) to the incubation buffer completely
abolished the lysis zones on the gels, confirming the
inhibitory activity of this compound (data not shown).
DISCUSSION
In this study, we investigated the expression of 16 MMPs
and 4 TIMPs in the fat pads of mice maintained for 15
weeks on SFD or HFD. Except for MMP-8, all MMP and
TIMP mRNAs analyzed were detected in both gonadal and
subcutaneous depots. Mature adipocytes, the major com-
ponent of the adipose tissue, expressed a limited number
of these transcripts, including MMP-12, -15, -19, and -24
and TIMP-3 and -4. However, the presence of contaminat-
ing endothelial cells in the adipocyte fractions (especially
those isolated from mice on SFD) might have affected the
expression profiles depicted in Table 3. Nevertheless, a
comparison with the expression profiles observed in adi-
pocytes isolated from mice on HFD, which contain ex-
tremely low levels of contaminating cells, indicated that
mature adipocytes expressed at least MMP-12 (in gonadal
fat), MMP-24, and TIMP-4. The expression of MMP-15 and
MMP-19, which were high in adipocytes derived from mice
on SFD, was extremely low or undetectable in adipocytes
FIG. 3. Expression of MMPs and TIMPs during in vitro adipogenesis. A: Total RNA was extracted from 3T3-F442A cells at different stages of
differentiation: pre, preconfluent; con, confluent (day 0); d5, d12, and d19, postconfluent cultures after 5, 12, and 19 days, respectively. RNA
samples were analyzed for MMP and TIMP mRNA levels by semiquantitative RT-PCR. Data were expressed as relative expression levels obtained
after normalization for the 28S rRNA levels. Secretion of MMPs and TIMPs by differentiating adipocytes into the serum-free culture medium was
analyzed by gelatin zymography (B) and reverse zymography (C), respectively.
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from mice on HFD, suggesting that the expression of these
mRNAs was either endothelial-specific or downregulated
in mature adipocytes when the mice received an HFD. In
contrast, stromal cells, which comprise preadipocytes,
fibroblasts, and blood vessels, expressed all MMP and
TIMP mRNAs.
In agreement with earlier studies (22), feeding the mice
an HFD led to the development of obesity. Nutritionally
induced obese mice showed a higher total body weight,
larger fat pads, and hypertrophic adipocytes. In addition to
these morphological changes, MMP and TIMP expression
profiles were profoundly altered. The mRNA levels of
MMP-3, -11, -12, -13, and -14 and TIMP-1 were upregulated,
whereas MMP-7, -9, -16, and -24 and TIMP-4 were down-
regulated. Most of these modulations were specific to the
gonadal fat (Table 4), supporting the concept that the
different depots are not identical (23). Such regional
variations in the regulation of MMPs could arise from
differences in cellular composition (e.g., gonadal fat con-
tains more S-V cells than subcutaneous fat) and/or from
regional differences in the secretion of proteins such as
interleukin-6 or leptin (24), which can affect MMP expres-
sion (25).
The catalytic activity of MMPs is tightly regulated and
primarily determined by the balance between the levels of
activated MMPs and TIMPs. Using fluorescent in situ
zymography, we were able to detect MMP-dependent
proteolytic activities in intact adipose tissue. Moreover,
daily injection of mice maintained on an HFD with galar-
din (a synthetic broad spectrum MMP inhibitor) resulted
in lower MMP-mediated proteolytic activities in fat pads
(H.R.L., E.M., L.B. Hansen, B. Van Hoef, L. Frederix, and
D.C., unpublished observation). Collectively, these data
demonstrated that in situ, the level of active MMPs ex-
ceeded the level of inhibitors.
Obesity has been associated with an extensive reorga-
nization of the adipose tissue involving adipogenesis,
angiogenesis, and ECM remodeling. A large body of evi-
dence has established that the ECM not only functions as
a structural support but also influences cell-cell interac-
tions, differentiation, and migration. Such functions may
be necessary for the cellular reorganization of fat pads as
well as for regulation of the expression of adipocyte genes.
Although several reports have demonstrated that ECM
components influence adipocyte differentiation in vitro,
few of them have addressed the potential contribution of
ECM remodeling.
Because of the pleiotropic functions attributed to MMPs
and TIMPs, it is likely that these molecules affect several
cellular processes in the fat depots. Indeed, MMPs are
collectively able to cleave a wide variety of substrates,
including ECM components, proteinases and inhibitors,
matrix receptors, and receptors involved in cell-cell inter-
actions (26). These functions suggest that MMPs could
facilitate adipose tissue remodeling by increasing matrix
plasticity. Moreover, adipocytes are surrounded by a base-
ment membrane (27) that has to be extensively remodeled
in order to allow the hypertrophic development of adipo-
cytes observed in obesity. In agreement with this hypoth-
esis, MMP-2 and -9, two major MMPs implicated in
basement membrane remodeling, were detected in murine
(28) and human mature adipocytes (29). MMPs can also
release, activate, or degrade several growth factors and
cytokines (26) implicated in obesity. MMPs also play
major roles in angiogenesis (30), an essential process for
the development of adipose tissue (6).
Formation of adipose tissue requires the conversion of
preadipocytes into mature adipocytes (31). This differen-
tiation switch activates a new program of gene expression
that is followed by the accumulation of lipids. We there-
fore examined the pattern of MMP and TIMP expression
during adipocyte differentiation, using 3T3-F442A preadi-
pocytes as an in vitro model of adipogenesis. It was
previously shown that differentiation of 3T3 preadipocytes
mimics the in vivo process, yielding cells expressing many
of the same genes as well as morphological and metabolic
characteristics of in vivo adipocytes (32,33).
Our data show that most MMP and TIMP transcripts
detected in vivo were also expressed and modulated in
vitro during differentiation. However, the comparison of
the patterns of gene expression between in vitro differen-
tiated adipocytes (Fig. 3) and isolated mature adipocytes
(Table 3) revealed some discrepancies. Whereas MMP-2,
-9, -11, and -16 and TIMP-2 mRNAs were expressed in in
vitro differentiated adipocytes, they were not detected in
isolated mature adipocytes. These discrepancies likely
result from the uncompleted differentiation observed in
vitro. Indeed, although a homogenous population of ma-
ture adipocytes was isolated from the fat pads, in vitro
adipogenesis generated a mixture of cells at different
stages of differentiation. Furthermore, adipocytes gener-
ated in vitro displayed a multilocular morphology that
differed from the unilocular adipocytes observed in vivo.
In agreement with these observations, recent reports
demonstrated that the changes in gene expression associ-
ated with adipocyte development in vivo and in vitro,
though overlapping, may be different in some respects
(33,34).
FIG. 4. Inhibition of in vitro adipogenesis by a synthetic MMP inhibitor.
Adipocyte differentiation was performed in the presence of a synthetic
MMP inhibitor. At day 0 of the differentiation process, confluent
3T3-F442A cells were treated with vehicle (E) or CT1746 (F, 10
mol/l) for 19 days. Adipocyte differentiation was monitored by flow
cytometry, and data were expressed as mean Nile Red fluorescence.
Results shown are representative of two independent experiments.
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Differentiation of 3T3-F442A cells was also associated
with the deposition of an abundant ECM (data not shown)
and the secretion of MMP-2 and -9. When the differentia-
tion procedure was performed in the presence of CT1746,
a synthetic MMP inhibitor that has a greater specificity for
MMP-2, -3, and -9 than for MMP-7 (35), the accumulation of
intracytoplasmic lipids was reduced, demonstrating the
implication of MMPs during adipogenesis. Nevertheless,
we cannot exclude the possibility that this synthetic
inhibitor may also influence adipogenesis by interfering
with other metalloproteinases such as the adamalysins.
Interestingly, when mice maintained on HFD for up to 12
weeks were daily injected with galardin, another synthetic
MMP inhibitor, a significant reduction of both gonadal and
subcutaneous fat pad weights was observed, although the
total body weight remained unchanged (H.R.L., E.M., L.B.
Hansen, B. Van Hoef, L. Frederix, and D.C., unpublished
observation). This observation further supports the hy-
pothesis that the catalytic activity of MMPs is important
for adipose tissue development.
In contrast with our data, Alexander et al. (36) recently
reported an accelerated lipogenesis in differentiating
3T3-L1 adipocytes treated with TIMP-1 or GM6001, a broad
spectrum MMP inhibitor. These conflicting observations
might arise from differences in experimental models
(3T3-L1 vs. 3T3-F442A cells), differentiation procedure
(serum-containing versus serum-free medium in current
study), and/or specificity of the inhibitors.
In conclusion, we have revealed that a large array of
MMPs and TIMPs are expressed in murine adipose tissue
as well as in differentiating 3T3-F442A preadipocytes. The
striking modulations of their expression in a model of
nutritionally induced obesity as well as their involvement
during in vitro adipogenesis suggest a functional role for
MMPs and TIMPs in the pathophysiology of the adipose
tissue.
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